Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-654-8 | CAS number: 27776-01-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Version / remarks:
- Study conducted prior to the adoption of the most recent version of this Guideline
- Deviations:
- yes
- Remarks:
- Individual bodyweights at study start were not indicated; some parameters, as age of animals at study start and humidity level during study, were not reported; sampling time was only 6 hours following end of treatment
- GLP compliance:
- no
- Type of assay:
- micronucleus assay
Test material
- Reference substance name:
- Benzyltoluene
- EC Number:
- 248-654-8
- EC Name:
- Benzyltoluene
- Cas Number:
- 27776-01-8
- Molecular formula:
- C14H14
- IUPAC Name:
- 1-benzyl-2-methylbenzene; 1-benzyl-3-methylbenzene; 1-benzyl-4-methylbenzene
- Details on test material:
- - Name of test material (as cited in study report): Ugilec 101
- Physical state: Clear colourless liquid
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- other: COBS CD-1 (ICR) BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, UK
- Age at study initiation: no data
- Weight at arrival: 18 - 21 g
- Assigned to test groups randomly: yes
- Fasting period before study: yes, overnight
- Housing: 2 or 5 animals/sex/cage
- Diet: laboratory diet ad libitum
- Water: tap water ad libitum
- Acclimation period: 10 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22
- Humidity (%): no data
- Air changes (per hr): 30
- Photoperiod (hrs dark / hrs light): 12
IN-LIFE DATES: no data
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: corn oil
- Justification for choice of solvent/vehicle: Ugilec 101 was miscible with corn oil
- Concentration of test material in vehicle: 12.5, 25.0, 50.0 mg/mL
- Amount of vehicle (if gavage or dermal): animals in all groups were dosed with the standard volume of 0.1 ml/10 g bodyweight (10 mL/kg bw) - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Ugilec 101 was prepared as a solution in corn oil using a high speed mixer. - Duration of treatment / exposure:
- 2 administrations separated by an interval of 24h.
- Frequency of treatment:
- daily
- Post exposure period:
- 6 hours
Doses / concentrationsopen allclose all
- Dose / conc.:
- 125 mg/kg bw/day (nominal)
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- mitomycin C
- Justification for choice of positive control(s): yes, a known mutagen (recommanded by OECD for this specific test)
- Route of administration: intraperitoneal injection
- Doses / concentrations: 4 mg/kg for 2 days
Examinations
- Tissues and cell types examined:
- - Tissues: Bone marrow smear from each femur
- Cells: Erythrocytes - Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
Based on the Maximal Tolerated Dose obtained from preliminary toxicity testing
TREATMENT AND SAMPLING TIMES ( in addition to information in specific fields):
Sampling was performed on dead animals sacrificed 6 hours after the last administration.
DETAILS OF SLIDE PREPARATION:
Following animal sacrifice, a direct bone marrow smear was made onto a slide containing a drop of calf serum. The slide was cleaned by immersion in methanol for 24 hours and air-dried immediately before use. One smear was made from each femur. The prepared smears were air-dried and fixed in methanol overnight. After fixation, the smears were air-dried and placed in buffered distilled water (pH 6.8) for 10 minutes prior to staining in Giemsa (dilution factor; 1 part Giemsa : 9 parts buffered distilled water, pH 6.8) for 10 minutes. After rinsing in buffered distilled water (pH 6.8), the slides were air-dried and mounted in DPX.
METHOD OF ANALYSIS:
The stained smears were coded and examined by light microscopy to determine the incidence of micronucleated cells per 2000 polychromatic erythrocytes per animal and the ratio of normochromatic to polychromatic erythrocytes. - Evaluation criteria:
- no data
- Statistics:
- no data
Results and discussion
Test results
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- at 500 mg/kg bw/d
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY
- Dose range:
Phase I (2 animals/sex/dose): 2 administrations from 250 to 9700 mg/kg bw/d (from 500 to 19400 mg/kg bw in total)
Phase II (5 animals/sex/dose): 2 administrations from 500 to 1000 mg/kg bw/d (from 2000 to 4000 mg/kg bw in total)
- Mortality (see Table 1 in the field Remarks on results)
- Clinical signs of toxicity:
After administration of Ugilec 101 at 250 mg/kg bw/d, no toxic reactions were observed.
At 1000 mg/kg bw/d, a toxic reaction consisting of hypopnoea and lethargy was observed 1 hour after the first dose and the symptoms were still present 7 hours later. However on the morning of the second day (24 hours after the first dose) the symptoms were not observed, but reappeared 1 hour after the second dose and were still present at the time of sacrifice, 5 hours later.
Between 1500 and 9700 mg/kg bw/d, a toxic reaction consisting of hypopnoea, ptosis and pale extremities were observed 1 hour after the first dose. In addition, ataxia and tremors were observed 2 hours later and all the symptoms were still present 4 hours later (8 hours after the first dose). However on the morning of the second day (24 hours after the first dose) the symptoms were not observed, but reappeared 1 and 3 hours later and were still present at the time of sacrifice, 6 hours after the second dose.
RESULTS OF DEFINITIVE STUDY (see Table 2 in the field Remarks on results)
- Mortality:
No mortality was observed in the low dose animal group.
One male treated at 250 mg/kg bw/d (500 mg/kg bw in total) was found dead 24 hours after the first treatment.
One male treated at 500 mg/kg bw/d (1000 mg/kg bw in total) was found dead 2 hours after the second treatment.
- Clinical signs of toxicity:
After administration of Ugilec 101 at dosages of 125 and 250 mg/kg bw/d (250 and 500 mg/kg bw in total, respectively) no toxic reactions were observed.
Dosage of 500 mg/kg bw/d (1000 mg/kg bw in total) produced a toxic reaction consisting of hypopnoea and lethargy which was observed 1 hour after the first dose and the symptoms were still present 7 hours later. However on the morning of the second day (24 hours after the first dose) the symptoms were not observed, but reappeared 1 hour after the second dose and were still present at the time of sacrifice, 5 hours later.
Macrocopic examination at post mortem was not possible for the animal dead in the mid-dose treated group, due to visceral autolysis, and failed to reveal any abnormalities in the high-dose treated dead animal.
- Induction of micronuclei (for Micronucleus assay):
After administration of Ugilec 101 at all total dosages, the group mean micronucleated cell counts were comparable with the concurrent control value.
- Ratio of NCE/PCE (for Micronucleus assay):
After administration of Ugilec 101 at all total dosages the group mean normochromatic to polychromatic cell ratios were comparable with the concurrent control value.
- Appropriateness of dose levels and route:
Toxic reactions observed in the micronucleus test as expected as they were similar to the reactions observed in prelimnary toxicity study at the same dose levels.
Any other information on results incl. tables
Table 1 Preliminary toxicity results
Test design |
Treatment (2 administrations at 24-h interval) |
Mortality ratio |
|
Males |
Females |
||
Phase I: |
Vehicle |
0/2 |
0/2 |
TS at 250 mg/kg bw/d |
0/2 |
0/2 |
|
TS at 2500 mg/kg bw/d |
2/2 |
2/2 |
|
TS at 5000 mg/kg bw/d |
2/2 |
2/2 |
|
TS at 7500 mg/kg bw/d |
2/2 |
2/2 |
|
TS at 9700 mg/kg bw/d |
2/2 |
2/2 |
|
Phase II: |
Vehicle |
0/5 |
0/5 |
TS at 1000 mg/kg bw/d |
4/5 |
4/5 |
|
TS at 1500 mg/kg bw/d |
5/5 |
3/5 |
|
TS at 2000 mg/kg bw/d |
5/5 |
5/5 |
Table 2 Micronucleus assay results
Treatment (2 administrations at 24-h interval) |
Sacrifice time |
Mean number of micronucleated cells per 2000 polychromatic erythrocytes per animal |
Mean ratio of normochromatic |
Vehicle |
30 |
1.8 |
1.7 |
TS at 125 mg/kg bw/d |
30 |
1.9 |
1.6 |
TS at 250 mg/kg bw/d |
30 |
1.4 |
1.4 |
TS at 500 mg/kg bw/d |
30 |
2.2 |
1.7 |
Mitomycin C at 8 mg/kg bw/d |
30 |
105.1 |
9.0 |
Applicant's summary and conclusion
- Conclusions:
- Ugilec 101 (benzyltoluene) did not present any in vivo genotoxic activity in the micronucleus test conducted in mice orally gavaged twice at 125, 250 and 500 mg/kg bw.
- Executive summary:
The genotoxicity of benzyl toluene (Ugilec 101) was determined in a micronucleus test conducted in vivo with COBS CD-1 (ICR) BR mice using a similar method to the OECD Guideline 474. Solutions were administered by gavage at a constant volume of 10 mL/kg bw. Following preliminary toxicity assay, 500 mg/kg bw/d treatment for 2 days was selected as the maximum tolerated dose, based on high rates of mortality and severe clinical signs observed at higher dosages. Doses of 125, 250, and 500 mg/kg bw/d were administered by oral gavage to groups of 10 mice (5 males and 5 females), in two equal dosages, separated by an interval of 24 hours. Mitomycin C, administered intraperitoneally at a total dose level of 8 mg/kg, served as positive control. Animal were sacrificed 6 hours after the second administration, and bone marrow smears examined for the presence of micronuclei in 2000 polychromatic erythrocytes per mouse and for the ratio NCE/PCE. No significant increased mortality was observed in any treated groups. Signs of toxicity were only observed at the dose of 500 mg/kg bw/d, consisting of hypopnoea, ptosis, ataxia and tremors. The NCE/PCE ratio obtained in all treated animals was similar to that of control animals. The number of micronucleated polychromatic cells in animals given benzyltoluene was similar to that obtained in control animals. Conversely, animals treated with Mitomycin C presented a highly significant increase in the number of micronucleated polychromatic cells. Benzyl toluene was concluded to be negative in the micronucleus test with mice.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.